Delivery Order SPE2DB24D3014-SPE2DB25FKUEB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $3,299.21. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 28, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Rexulti 2 mg tablets (quantity: 30 units) with a ceiling value of $2,927.61. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $3,228.07. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for ultimate completion by July 24, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Rexulti 2 mg tablets (30-count packages) with a ceiling value of $9,967.07. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 8, 2025, and will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating open competition among qualified...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package, with a contract ceiling value of $4,260.21. This non-set-aside, competitively awarded delivery order represents a firm fixed price transaction and is scheduled for completion by August 15, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Rexulti 2 mg tablets (30-count packages) with a ceiling value of $15,853.82. This competitively awarded, firm fixed-price delivery order is non-set-aside and carries an ultimate completion date of July 25, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count) on August 13, 2025, with a ceiling value of $1,002.23 and firm fixed pricing. This delivery order is non-set-aside and represents a competitive award to the pharmaceutical distributor, with an ultimate completion date of August 14, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rexulti 0.5 mg tablets (30-count) with a ceiling value of $1,952.46. This is a firm fixed price delivery order with no set-aside designation, issued under a competitive process. The contract is due for completion by August 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a child order under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Rexulti 2 mg tablets (30-count units) valued at $12,358.69. This is a firm fixed price, non-set-aside delivery order with a completion date of September 16, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's extensive role as a critical pharmaceutical supplier to the federal...
- SPE2DB24D3014Indefinite Delivery Contract
- SPE2DB24D3014-SPE2DB25FKUEBDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $9,482.33. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion on August 1, 2025, and the place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military and veteran healthcare systems. The Rexulti pharmaceutical product falls within the company's extensive portfolio of neurological and specialty medications delivered to the Defense Health Agency and other government healthcare entities through this primary vendor agreement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.5k | 7/31/25 |